[The effect of exenatide analogs on hydruretic function of rat kidney under water load].
Eksp Klin Farmakol · 2012
Last updated 2026-05-28In a study on rats, a drug called exenatide and two of its modified versions (analog I and analog II) were injected at a dose of 0.05 nmol per 100 grams of body weight. All three increased urine production and the excretion of sodium, magnesium, and potassium, but only exenatide and analog I also increased the excretion of solute-free water, which may be relevant for kidney function.
AI summary of the abstract below.
| Journal | Eksp Klin Farmakol, 2012 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | exenatide |
Abstract
Injection (0.05 nmol/100 g b.w.) of exenatide or its amino-acid-substituted synthetic analogs I (substitution at positions 14 and 39) and II (substitution at positions 14, 35, and 39) led to an increase in diuresis and excretion of sodium, magnesium and potassium, but only exenatide caused the excretion of solute free water. In experiments with 1% water load, only exenatide analog I stimulated the solute free water excretion. These features of exenatide and its analogs show the possibility of searching for substances with various power of action upon ion and water excretion by the kidney, which may have a clinical significance.
Verbatim abstract via PubMed 23323326 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.